Analytical and clinical evaluation of the PathoNostics AsperGenius Assay for detection of invasive aspergillosis and resistance to azole antifungal drugs directly from plasma samples by White, P. Lewis et al.
1 
 
Title: An analytical and clinical evaluation of the PathoNostics AsperGenius® Assay for the detection 1 
of invasive aspergillosis and resistance to azole antifungal drugs direct from plasma samples. 2 
 3 
Authors: P. Lewis White1, Raquel B. Posso2 and Rosemary A. Barnes2 4 
Affiliations:  1Public Health Wales Microbiology Cardiff, UK; 2Infection, Immunity and Biochemistry, 5 
School of Medicine, Cardiff University, UK.  6 
 7 
Corresponding Author: P. Lewis White. 8 
Address: Public Health Wales Microbiology Cardiff, UHW, Heath Park, Cardiff, CF14 4XN, UK. 9 
Telephone: +44 (0)29 2074 6581  10 
Fax: +44(0) 29 2074 2161 11 
Email: lewis.white@wales.nhs.uk 12 
 13 
Key words: Invasive aspergillosis, Aspergillus PCR, azole resistance determination. 14 
15 
2 
 
ABSTRACT 16 
With the proposal to include Aspergillus PCR in the revised EORTC/MSG definitions for fungal 17 
disease, commercially manufactured assays may be required to provide standardisation and 18 
accessibility. The PathoNostics AsperGenius® assay represents one such test that has the ability to 19 
detect a range of Aspergillus species and azole-resistance in A. fumigatus. Performance has been 20 
validated when testing BAL and serum specimens, but recent evidence suggests that testing plasma 21 
may enhance sensitivity over serum. It was decided to evaluate the analytical and clinical 22 
performance of the PathoNostics AsperGenius® assay when testing plasma. 23 
For the analytical evaluations plasma was spiked with various concentrations of Aspergillus genomic 24 
DNA before extraction following international recommendations using two automated platforms. 25 
For the clinical study, 211 samples from 10 proven/probable IA and 2 possible IA cases, and 27 26 
controls were tested.  27 
The limit of detection when testing DNA extracted using the BioMerieux EasyMag and Qiagen EZ1 28 
extractors was five and 10 genomes/0.5ml sample, respectively. In the clinical study, true positivity 29 
was significantly greater than false positivity (P: <0.0001). The sensitivity and specificity using a 30 
single positive result as significant were 80% and 77.8%, respectively. If multiple samples were 31 
required to be positive specificity was increased to 100%, albeit sensitivity reduced to 50%.  32 
Summary: The AsperGenius® assay provided good clinical performance but the predicted 33 
improvement when testing plasma was not seen, possibly a result of target degradation attributed 34 
to sample storage. Prospective testing is required to determine the clinical utility of this assay, 35 
particularly the diagnosis of azole-resistant disease.  36 
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INTRODUCTION 37 
Standardisation of Aspergillus PCR testing of blood based samples has led to the proposal to include 38 
Aspergillus PCR in to the second revision of the EORTC/MSG consensus definitions for invasive fungal 39 
disease (IFD). 1-4 This may increase demand for Aspergillus PCR, as it can be used, in combination 40 
with other biomarker assays (Galactomannan EIA and β-D-Glucan) to improve management of 41 
patients at risk of invasive aspergillosis (IA). 5 Easily attainable, quality controlled and well validated 42 
assays are necessary, and commercially developed assays help in achieving these requirements. 43 
Several commercial Aspergillus PCR assays have been developed (MycAssay Aspergillus, Renishaw 44 
Fungiplex, Ademtech MycoGENIE, PathoNostics AsperGenius®) with varying degrees of clinical 45 
validation. 6-10 Of particular interest, given the emergence of azole resistant strains of A. fumigatus, 46 
are the Ademtech MycoGENIE and PathoNostics AsperGenius® assays that have the ability to detect 47 
the major single nucleotide polymorphisms that infer environmentally driven resistance. Tests to 48 
detect genetic mechanisms of azole resistance have been applied directly to clinical samples and 49 
have the potential to overcome the limited sensitivity of conventional culture techniques. 7, 8 The 50 
application of these tests to non-invasive sample types (e.g. blood) will improve clinical utility and 51 
some success has been noted when testing serum. 7 52 
Recently, the European Aspergillus PCR initiative showed that both the analytical and clinical 53 
performance of Aspergillus PCR was superior when testing plasma compared to serum. 3, 4 It was 54 
proposed that using plasma avoided DNA trapping during clot formation, subsequently the available 55 
target was greater and performance enhanced. In the previous evaluation of the PathoNostics 56 
AsperGenius® assay when testing serum the sensitivity and specificity were 79% and 91%, 57 
respectively, and genetic screening for resistance direct from the sample was obtained in 50% of the 58 
cases.7 It is hypothesised the testing of plasma may improve the performance of the AsperGenius® 59 
assay. Nevertheless, validation when testing plasma is required to enhance the application range 60 
and assay robustness. 61 
4 
 
This manuscript determines the analytical and clinical performance of the PathoNostics 62 
AsperGenius® assay when testing plasma samples using methods in line with international 63 
recommendations. 464 
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MATERIALS AND METHODS 65 
Study design 66 
The study was divided into an analytical evaluation to determine the assays limit of detection (LOD), 67 
linear range and efficiency of amplification when testing plasma, and  secondly, a clinical study to 68 
determine performance (sensitivity/specificity etc) when testing plasma samples from a 69 
haematology population at high risk of IA.  70 
 71 
Analytical Study 72 
The analytical evaluation focused on performance when detecting specimens containing genomic 73 
DNA from A. fumigatus or A. terreus. Two automated nucleic acid extraction systems were evaluated 74 
(Qiagen DSP virus kit on the EZ1 Advance XL instrument and BioMerieux Generic 2.01 Protocol on 75 
the EasyMag instrument). All nucleic acid was eluted in 60µl.  76 
Simulated plasma samples were prepared using pooled human plasma divided into 0.5ml aliquots 77 
and spiked with various concentrations of genomic DNA from either A. fumigatus or A. terreus  to 78 
achieve final burdens of 10000, 1000, 500, 100, 75, 50, 25, 10, five, one genome/0.5 ml sample. 79 
Successful detection of the higher burdens was predicted, so in order to determine accurate 80 
performance at less predictable concentrations the number of replicates was greater when testing 81 
lower burdens (Tables 1-3). To monitor for contamination during each extraction process at least 82 
one non-spiked plasma aliquot was retained to provide a negative control. To avoid airborne 83 
contamination, all required manual processes took place in a class II laminar flow cabinet.  84 
When performing PCR amplification a five microlitre DNA template input volume was used for all 85 
burdens, with an additional  10µl input assessed for the lower burdens (<50 genomes/0.5ml sample) 86 
in an attempt to improve reproducibility of detection. 87 
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Clinical Study and Patient Population 88 
Clinical plasma samples from patients with proven, probable, possible IA, or with no evidence of 89 
fungal disease (NEF) were selected. All samples had been sent as part of the care pathway 90 
incorporating a well-validated “in-house” Aspergillus PCR. 11, 12 On completion of routine testing 91 
plasma was stored at -80˚C for quality control or performance assessment purposes. The study was a 92 
performance assessment of the AsperGenius® Assay and was an anonymous, retrospective 93 
case/control design, not effecting patient management. Patient demographics are shown in Table 4. 94 
Nucleic acid was extracted from 0.5ml of plasma using the BioMerieux EasyMag Generic 2.01 95 
Protocol, following the manufacturer’s instructions, with DNA eluted in 60µl. Positive (plasma 96 
containing 10 genomes of A. fumigatus DNA) and negative (plasma only) extraction controls were 97 
included in each run.  98 
When performing PCR amplification a 10µl DNA template volume was used to provide optimal 99 
opportunity for detection. 100 
 101 
PathoNostics AsperGenius® PCR amplification 102 
For both the analytical and clinical studies the AsperGenius® species and resistance PCR testing was 103 
performed on the Qiagen Rotorgene Q High Resolution Melt Instrument. Using a final reaction 104 
volume of 25µl and following the manufacturer’s instructions, with the exception that DNA template 105 
volumes for the species assay were increased to 10µl for the clinical evaluation, and in the analytical 106 
evaluation where performance for detection of the lower burdens (<50 genomes/0.5ml sample) was 107 
compared with an input volume of five microlitres. The manufacturer recommends an input volume 108 
of five and 10µl for the species and resistance assays, respectively.  109 
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Statistical Evaluation  110 
Analytical analysis of the AsperGenius® species PCR when testing plasma samples was performed as 111 
previously described. 7 Briefly, the 100% LOD, linearity ranges and PCR amplification efficiencies 112 
were calculated. Further analysis was performed correlating AsperGenius® species and resistance 113 
performance so that the quantification cycle (Cq) generated by the A. fumigatus assay could be used 114 
as a guide to the likelihood of success when performing the resistance assay.  115 
When determining the clinical accuracy of the AsperGenius® species results the positivity rate in 116 
samples originating from cases was compared to the false positivity rate in control samples. Clinical 117 
performance was determined by the construction of 2x2 tables to calculate sensitivity, specificity, 118 
positive and negative likelihood ratios and diagnostic odds ratio of the AsperGenius® species assay. 119 
For all patients, only a single positive sample was required to consider the patient positive. Given the 120 
case control study design, and artificially high prevalence of proven/probable IA (25.6%), predictive 121 
values were not used. When required ninety-five percent confidence intervals and, P values (Fishers 122 
exact test; P: 0.05) were generated to determine the significance of the difference between rates.  123 
124 
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RESULTS 125 
Analytical Performance of the AsperGenius® species assay. 126 
When extracting DNA from plasma using the Qiagen EZ1 DSP virus kit the LOD for both the A. 127 
fumigatus specific and Aspergillus species assays was 25 genomes/0.5ml sample using a 5µl 128 
template input and 10 genomes/0.5ml sample using a 10µl template input volume (Table 1). 129 
Increasing the amount of DNA template also improved reproducibility when detecting 130 
5genomes/0.5ml sample but did not improve detection of 1 genome/0.5ml sample. 131 
Using the BioMerieux EasyMag for DNA extraction, the LOD using a five microlitre template input for 132 
both the A. fumigatus and Aspergillus spp. assays improved to five genomes/0.5ml sample, 133 
compared to the equivalent volume of eluate extracted by the Qiagen EZ1 DSP virus kit (Tables 1 and 134 
2). However, 4/31 replicates across all burdens generated a low level false positive A. terreus result 135 
(Mean Ct: 42.4).  Increasing the template input volume to 10µl did not improve the 100% LOD, but 136 
reproducibility when detecting one genome/0.5ml sample was improved (A. fumigatus assay 10µl 137 
template: 3/5 vs 5µl template 0/5; Aspergillus spp. assay 10µl template: 3/5 vs 5µl template 1/5).  138 
When using the BioMerieux EasyMag to extract A. terreus DNA from plasma the LOD for both the A. 139 
terreus specific and Aspergillus species targets was five genomes/0.5ml sample using 5 µl of DNA 140 
template, at one genome/0.5ml sample reproducibility for both targets was 33.3%. Increasing the 141 
input to 10µl per reaction lowered the LOD to one genome/0.5ml sample (Table 3). 142 
For the A. fumigatus and Aspergillus spp. assays amplification was linear from 5-10000 143 
genomes/0.5ml sample when testing EZ1 extracts (Figure 1a). The PCR efficiency using DNA 144 
extracted from plasma by the EZ1 was 96.3% and 118.5% for the A. fumigatus and Aspergillus spp. 145 
assays, respectively. When testing EasyMag extracts the linear range was also 5-10000 146 
genomes/0.5ml sample for the A. fumigatus assay, but for the Aspergillus spp. assay it was 1-10000 147 
genomes/0.5ml sample (Figure 1b). The PCR efficiency using DNA extracted from plasma by the 148 
EasyMag was 73.8% and 119.9% for the A. fumigatus and Aspergillus spp. assays, respectively. The 149 
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linear range for both assays when testing A. terreus DNA extracted by the EasyMag was 1-10000 150 
genomes/0.5ml sample (Figure 1c). The PCR efficiency testing A. terreus DNA extracted from plasma 151 
by the EasyMag was 107.3% and 118.3% for the A. terreus and Aspergillus spp. assays, respectively. 152 
 153 
Analytical Performance of the AsperGenius® resistance assay. 154 
The 100% LOD for all resistance markers was 50 genomes/0.5ml sample and non-reproducible 155 
detection was achieved at 25 genomes/0.5ml sample (50-75% reproducibility) 10 genomes/0.5ml 156 
sample (20% reproducibility). At five genomes/0.5ml sample only the region potentially containing 157 
the TR34 mutation amplified on 1/5 occasions, all other targets were consistently negative (0/5) at 158 
this burden. All targets failed to amplify when testing nucleic acid extracted from samples containing 159 
one genome of A. fumigatus DNA. This information was used to determine a minimum fungal 160 
burden in a plasma sample that would permit successful amplification of the regions containing the 161 
potential resistance markers. For reproducible detection of these markers the burden would need to 162 
be ≥50 genomes/0.5ml sample, corresponding to a Cq value <34 cycles when detecting DNA 163 
extracted by the EasyMag using the A. fumigatus specific assay. With non-reproducible detection of 164 
resistance markers expected when testing burdens between five and <50 genomes/0.5ml sample, 165 
testing A. fumigatus specific positive samples with Cq values between >33 and <39 cycles may result 166 
in successful amplification of regions potentially harbouring mutations inferring azole resistance.   167 
 168 
Clinical Evaluation 169 
There were 86 samples from 12 cases of IA tested, including 10 cases of proven/probable IA (72 170 
samples) and two cases of possible IA (14 samples). Unfortunately, no cases were culture positive 171 
and it was not possible to derive a species level of diagnosis. The median number of samples tested 172 
per case patient was seven (range 6-9).  There were 125 samples from 27 patients with no evidence 173 
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of invasive fungal disease included as controls; the median number of extracts tested per control 174 
patient was five (range 3-5). 175 
The positivity rate associated for samples from proven/probable cases, was 15.3% (11/72; 95% CI: 176 
8.8-23.5) and 25.0% (18/72; 95% CI: 16.4-36.1) for the A. fumigatus and Aspergillus spp. targets, 177 
respectively. All 11 A. fumigatus positive results were concomitantly positive by the Aspergillus spp. 178 
assay, and there were seven additional positives by the Aspergillus spp.  assay (Figure 2). Of the 179 
seven additional positive Aspergillus spp. assay results, four were from two patients that also had 180 
other samples positive by both A. fumigatus and spp. assays, and three were from two patients that 181 
were consistently negative by the A. fumigatus assay (Figure 2). The false positivity rate for samples 182 
from controls was 0.0% (0/125; 95% CI: 0.0-3.0) and 4.8% (6/125; 5% CI: 2.2-10.1) for the A. 183 
fumigatus and Aspergillus spp. targets, respectively. No samples (n=14) from possible patients (n=2) 184 
were positive by either assay. For both the A. fumigatus and Aspergillus spp. assays the true 185 
positivity for proven/probable IA cases, was significantly greater than false positivity associated with 186 
the control population (A. fumigatus assay: Difference 15.3%, 95% CI: 8.1-25.3, P: <0.0001; 187 
Aspergillus spp. assay: Difference 20.2, 95% CI: 10.1-31.6, P: <0.0001). There were two cases of 188 
potential non-fumigatus disease but no positive results were generated by the A. terreus specific 189 
assay. Given the lower PCR efficiency of the A. fumigatus assay it cannot be confidently determined 190 
whether species positive/A. fumigatus negative results represent infection by species other than A. 191 
fumigatus. Unfortunately, no culture data was available to provide species level identification. 192 
The mean Cq value for true positive samples was 39.4 (SD: ±4.0) and 35.9 cycles (SD: ±2.5) for the A. 193 
fumigatus and spp. assays, respectively. The mean Cq value for Aspergillus spp. false positive results 194 
was 37.1 (SD: ±1.4), later than Cq values for true positives, although numbers were limited.   195 
The overall combined clinical performance of the AsperGenius® assay is shown in Table 5. When 196 
using a single positive PCR result to define patient positivity only 6/10 proven/probable cases were 197 
positive by the A. fumigatus assay, compared to 8/10 by the Aspergillus spp. assay. Conversely, 198 
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specificity for the A. fumigatus assay was 100% (27/27) compared to 77.8% (21/27) for the 199 
Aspergillus spp. assay, and a multiple positive PCR threshold was required to attain 100% specificity 200 
for the latter. 201 
The amplification of regions harbouring potential mutations associated with azole resistance direct 202 
from a sample was only successful for two patients, and neither contained the TR34/L98H or 203 
TR46/T289A/Y121F mutations. Amplification was unsuccessful in a further four probable IA cases.  204 
205 
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DISCUSSION 206 
The performance of the PathoNostics AsperGenius® assay for the detection of Aspergillus DNA in 207 
plasma samples was satisfactory. Both sensitivity (80%) and specificity (78%) were comparable to 208 
that generated by meta-analytical reviews when testing blood, where sensitivity ranged from 84-209 
88% and specificity ranged from 75-76%. 13, 14 In the previous published evaluations of the 210 
AsperGenius® assay sensitivity and specificity when testing BAL was 84% and 91%, respectively, and 211 
when testing serum it was 79% and 91%, respectively. 7, 8 While sensitivity appears consistent across 212 
the specimen type, specificity when testing plasma was compromised, although numbers were 213 
limited in all studies. In both the serum and BAL studies optimal positivity thresholds could be 214 
defined, and in the case of serum testing a threshold of 39 cycles improved specificity to 100%, 215 
without compromising sensitivity. 7, 8 In the current study, it was not possible to generate a threshold 216 
as false positive results had Cq values similar to true positive results from cases of aspergillosis. As 217 
with serum testing, if more than one sample was positive per patient then specificity was 100%, but 218 
sensitivity was duly compromised (Table 5). 7 219 
In the recent studies of the EAPCRI, it was shown that the analytical and subsequent clinical 220 
performance of Aspergillus PCR could be improved by testing plasma over serum. 3, 4 It was 221 
hypothesised that when performing the AsperGenius® assay on DNA extracted from plasma an 222 
improvement in performance would have been evident. From an analytical performance this was 223 
observed, comparing PCR efficiency when testing five microlitres of DNA extracted from serum and 224 
plasma using the EZ1 showed the PCR efficiency for the both A. fumigatus and Aspergillus spp. 225 
assays improved when testing plasma (A. fumigatus assay serum (72.6%) vs plasma (96.3%); 226 
Aspergillus spp. assay serum (106%) vs plasma (118.5%).7 Conversely, the PCR efficiency for the A. 227 
fumigatus assay when testing DNA extracted using the EasyMag was superior for serum (A. 228 
fumigatus assay: 97%;  Aspergillus spp. assay: 124%) over plasma (A. fumigatus assay: 74%;  229 
Aspergillus spp. assay: 120%). 7 Highlighting that PCR efficiency can be severely compromised by the 230 
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quality of the nucleic acid extracted and the necessity to optimise the extraction process for each 231 
sample type. However, if the standard-curve of the A. fumigatus assay when testing DNA extracted 232 
by EasyMag is examined in detail (Figure 1b) it could be argued that the detection of burdens 233 
≤10genomes/0.5ml sample is outside the linear range of the assay. Removal of these burdens from 234 
the standard curve increases the coefficient of determination to 0.99 and PCR efficiency to 90%, 235 
comparable to testing DNA extracted from serum by EasyMag.  236 
In a previous study comparing the analytical performance of automated nucleic acid extraction 237 
platforms when performing Aspergillus PCR, the EasyMag was associated with high quality DNA and 238 
subsequent earlier Cq values, but was also associated with Aspergillus contamination. 15 The increase 239 
in PCR efficiency when testing DNA extracted from plasma by EZ1 was not significantly associated 240 
with an improved LOD for either assay, although using the EasyMag extractor and a larger DNA 241 
template volume did improve recovery of lower burdens. The reproducibility of detection when 242 
testing one genome/0.5ml sample extracted using the EasyMag was 60% (Table 2). There were four 243 
false positive A. terreus results in the analytical study, whereas false positivity in the clinical study 244 
was associated with the Aspergillus spp. target. No negative extraction control samples generated 245 
false positive results. Given the different identity of the false positivity in the clinical and analytical 246 
arms and the low level of overall false positivity it was felt that this was not directly associated with 247 
the EasyMag extractor, as previously documented, but represented false positivity typically 248 
encountered when testing clinical samples or analytical cross reactivity between Aspergillus 249 
species.15 250 
For all clinical samples 10µl of EasyMag extract was used for PCR amplification. This did not result in 251 
improved clinical performance, with no significant improvement in sensitivity but a reduction in 252 
specificity meaning the diagnostic odds ratio was less when testing plasma over serum. One 253 
potential explanation for this unexpected result is that while the use of the larger volume potentially 254 
increased the reproducibility of detection of the lower burdens (<10 genomes/0.5ml sample) these 255 
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low concentrations are more likely to be affected by sample degradation. Given the retrospective 256 
nature of the study, it is hypothesised that samples containing low burdens had degraded to below 257 
detectable levels minimising any benefits associated with using a larger template volume. 258 
 A second explanation for the lack of improvement in clinical performance is although the larger 259 
input volume increases the opportunity for detecting target DNA it also increases the potential for 260 
the presence of inhibitory compounds. Only two extractions exhibited total inhibition (no IC signal 261 
present), a further three generated Cq values that were later than upper limit generated by the 262 
manufacturer indicating a degree of partial inhibition. Of concern when interpreting the IC when 263 
testing plasma or serum is the relative high concentration of IC in respect to typical Aspergillus PCR 264 
positives in blood, and the subsequent acceptable IC Cq range proposed by the manufacturer. The 265 
acceptable Cq values for the IC range between 29.5-35.0 cycles, in this study 86.2% (182/211) of 266 
samples had an IC Cq value within this range, with 2.4% (5/211) of samples exhibiting partial or total 267 
inhibition (Cq >35.0 cycles). A further 11.4% (24/211) of samples had an IC Cq value below the lower 268 
acceptable limit (range: 26.1-29.4 cycles) and while this cannot represent inhibition it questions the 269 
robustness of the IC PCR when testing DNA template input volumes greater than the 5µl 270 
recommended by the manufacturer. This diversity (median IC Cq: 33.6 cycles, range: 26.1-36.4 271 
cycles) makes it difficult to determine a typical (expected) reference value from which inhibition in 272 
specimens can be derived. The relatively high IC concentrations, was developed for use with BAL 273 
samples where fungal burdens will be greater and earlier Cq values generated. Consequently, the 274 
typical IC value is significantly lower than that for Aspergillus PCR positives when testing serum and 275 
plasma samples (typically >35 cycles). As such the effect of any inhibitory compounds on the IC PCR 276 
may be less evident than that experienced on a clinical plasma sample where an inhibitory delay of 277 
2-3 cycles will result in PCR negativity, but keep the IC Cq within the manufacturer’s acceptable 278 
range resulting in potential false negative results. 279 
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In addition to inhibitory compounds the presence of interfering substances should also be 280 
considered. In a previous EAPCRI study the presence of fibrinogen in plasma was proposed to have 281 
the potential to influence magnesium concentration, which is critical to optimal PCR performance. 4 282 
It is possible that fibrinogen is present in nucleic acid eluates and this could interfere with PCR 283 
amplification. Using the larger input volume this could have affected the performance of the 284 
AsperGenius® assay and could explain the wide ranging IC Cq values, explaining why the mean Cq 285 
values for 2/5 simulated samples extracted using the Qiagen EZ1 and amplification performed using 286 
10µl of template had very late IC Cq values (Table 1). 287 
Although the use of 10µl of EasyMag eluate improved the detection of low burdens PCR efficiency 288 
using 10µl template was not calculated as the range of burdens tested using a 10µl input was limited 289 
to 1log. A further limitation of the study it was not possible to perform a direct comparison with the 290 
previous serum study and the samples included were different. With hindsight it may have been 291 
wise to perform the plasma testing using five microlitres of template, as the improvement in 292 
efficiency over serum was confirmed and this volume was used for the previous serum study. 7 293 
Currently, the AsperGenius® assay is only validated for in vitro diagnostic testing of BAL samples and 294 
this has implications when interpreting positive results from blood samples.  The positivity threshold 295 
for the species assay when testing BAL is <36 cycles, when testing blood this is likely too early with a 296 
median Cq of 35.9 cycles for clinical PCR positives and 11/18 (61.1%) having Cq values ≥36.0 cycles. It 297 
is important to remember that when testing blood specimens by Aspergillus PCR the strategy is to 298 
exclude disease using a negative result generated by frequent screening with a highly sensitive 299 
assay, subsequently a Cq threshold is not essential, albeit at the expense of false positive results.  300 
The regions potentially associated with azole resistance were only successfully amplified from two 301 
cases of IA. Given the costs associated with both the AsperGenius® species multiplex (Approx. 302 
$1000/50 reactions) and the AsperGenius® resistance multiplex (Approx. $1600/50 reactions of both 303 
species and resistance multiplex) it may be difficult to justify the costs associated with direct from 304 
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plasma resistance testing. However, if direct resistance testing was only applied to samples strongly 305 
positive by the species assay then wastage associated through failed amplification could be limited. 306 
Costs for screening with the species assay could be offset by reductions in the unnecessary use of 307 
antifungal therapy, as seen in other studies where Aspergillus PCR, in combination with 308 
galactomannan ELISA, was shown to reduce empirical therapy. 16-18 309 
To conclude, the PathoNostics AsperGenius® assay can be used to perform PCR testing on plasma 310 
and will provide performance that is comparable to testing serum. Unexpectedly, the predicted 311 
improvements in clinical performance associated with plasma testing were not seen, possibly a 312 
result of the retrospective study design or the impact of larger concentration of 313 
inhibitory/interfering compounds. Considering the latter, the current IC for the PathoNostics 314 
AsperGenius® assay showed too much variability to confidently predict inhibition, although this 315 
could be a result of using a larger template volume. The study also highlights the necessity to 316 
individually evaluate PCR assays when testing different specimen types.  Assays will have varying 317 
master-mix compositions and reaction kinetics, which may not be optimal across samples and 318 
subsequent eluate make-up. The clinical utility of commercially available Aspergillus PCR assays, 319 
such the AsperGenius® assay, require prospective evaluation with particular reference to the impact 320 
of potential early diagnosis of azole-resistant disease on patient management. 321 
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Table 1. Analytical performance of the PathoNostics AsperGenius® species assay when testing A. fumigatus genomic DNA extracted from plasma samples 413 
using the Qiagen EZ1 Advance XL instrument.  414 
 
Fungal load  
(genomes/ 
0.5ml sample) 
PathoNostics AsperGenius® target 
A. fumigatus Aspergillus spp. A.terreus Internal Control 
Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) 
D
N
A
 
t
e
m
p
l
a
t
e
 
V
o
l
u
m
e
:
 
 
5
µ
L
 
10000 7/7 27.21 (0.63) 7/7 26.18 (0.56) 0/7 - 7/7 31.33 (2.02) 
1000 7/7 30.16 (0.54) 7/7 29.07 (0.37) 0/7 - 7/7 32.57 (2.62) 
500 7/7 31.37 (0.61) 7/7 30.30 (0.35) 0/7 - 7/7 32.79 (2.26) 
100 7/7 34.6 (1.55) 7/7 32.60 (0.40) 0/7 - 7/7 33.53 (2.44) 
75 9/9 34.26 (0.75) 9/9 33.14 (1.23) 0/9 - 9/9 32.65 (2.18) 
50 9/9 35.47 (1.13) 9/9 34.15 (0.70) 0/9 - 9/9 33.19 (2.72) 
25 12/12* 37.29 (1.40) 12/12* 35.41 (1.24) 0/12* - 12/13* 33.30 (1.87) 
10 11/15 37.62 (1.63) 12/15 35.33 (0.80) 0/15 - 15/15 30.67 (3.82) 
23 
 
5 4/15 38.94 (1.23) 5/15 36.53 (0.78) 0/15 - 15/15 32.95 (2.41) 
1 3/15 39.82 (1.29) 4/15 37.14(0.78) 0/15 - 15/15 32.39 (2.56) 
0 0/15 - 0/15 - 0/15 - 15/15 30.49 (2.81) 
D
N
A
 
t
e
m
p
l
a
t
e
 
V
o
l
u
m
e
:
 
1
0
 
µ
L
 
25 3/3 37.57 (1.22) 3/3 34.60 3/3 - 3/3 39.14 (1.05) 
10 10/10 38.69 (2.07) 10/10 35.86 10/10 - 10/10 32.45 (1.79) 
5 5/10 42.62 (4.23) 5/10 37.66 5/10 - 10/10 31.73 (2.72) 
1 2/10 40.40 (1.13) 2/10 36.95 2/10 - 10/10 32.09 (2.15) 
0 0/5 - 0/5 - 0/5 - 5/5 38.99 (3.08) 
* One sample was deemed inhibitory to PCR amplification, as such only 12 replicates were included in the analysis of the A. fumigatus, A. terreus and 415 
Aspergillus species assays, whereas 12/13 replicates are shown for the corresponding internal control PCR. 416 
  417 
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Table 2. Analytical performance of the PathoNostics AsperGenius® species assay when testing A. fumigatus genomic DNA extracted from plasma samples 418 
using the BioMerieux EasyMag instrument. 419 
 420 
 
Fungal load  
(genomes/ 
0.5ml sample) 
PathoNostics AsperGenius® target 
A. fumigatus Aspergillus spp. A.terreus Internal Control 
Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) 
D
N
A
 
t
e
m
p
l
a
t
e
 
v
o
l
u
m
e
:
 
5
µ
L
 
10000 1/1 24.72 1/1 23.86 1/1 41.95 1/1 29.68 
1000 1/1 27.93 1/1 26.55 0/1 - 1/1 32.25 
500 1/1 28.85 1/1 27.23 0/1 - 1/1 31.67 
100 1/1 31.26 1/1 29.43 0/1 - 1/1 32.43 
50 3/3 33.24 (0.98) 3/3 30.75 (0.81) 1/3 39.39 3/3 33.33 (0.67) 
25 3/3 34.31 (1.79) 3/3 31.20 (0.61) 1/3 42.10 3/3 33.57 (0.80) 
10 5/5 37.5 (1.63) 5/5 32.5 (0.41) 0/5 - 5/5 31.86 (0.61) 
5 5/5 38.0 (2.66) 5/5 33.28 (0.73) 0/5 - 5/5 33.27 (0.82) 
1 0/5 - 1/5 35.35 1/5 43.90 5/5 33.48 (1.00) 
0 0/5 - 0/5 - 0/5 - 5/5 31.83(1.56) 
  421 
25 
 
D
N
A
 
t
e
m
p
l
a
t
e
 
V
o
l
u
m
e
:
 
1
0
 
µ
L
 
10 1/1 35.82 1/1 34.46 0/5 - 1/1 33.15 
5 5/5 38.65 (1.90) 5/5 35.80 (1.15) 0/5 - 5/5 30.56 (1.00) 
1 3/5 40.67 (2.14) 3/5 36.94 (1.45) 0/5 - 5/5 31.59 (1.77) 
0 0/5 - 0/5 - 0/5 - 5/5 32.60 (1.25) 
 422 
  423 
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Table 3. Analytical performance of the PathoNostics AsperGenius® species assay when testing A. terreus genomic DNA extracted from plasma samples using 424 
the BioMerieux EasyMag instrument. 425 
 426 
 
Fungal load  
(genomes/ 
0.5ml sample) 
PathoNostics AsperGenius® target 
A. fumigatus Aspergillus spp. A.terreus Internal Control 
Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) Positives/total Mean Cq (SD) 
D
N
A
 
t
e
m
p
l
a
t
e
 
v
o
l
u
m
e
:
 
5
µ
L
 
10000 0/1 - 1/1 24.30 1/1 26.10 1/1 30.21 
1000 0/1 - 1/1 27.40 1/1 29.14 1/1 32.49 
500 0/1 - 1/1 27.98 1/1 30.23 1/1 33.37 
100 0/2 - 2/2 30.14 (0.04) 2/2 32.48 (0.05) 2/2 33.82 (0.21) 
75 0/2 - 2/2 30.34 (0.38) 2/2 32.69 (0.39) 2/2 30.86 (1.51) 
50 0/2 - 2/2 31.30 (0.18) 2/2 33.67 (0.06) 2/2 33.43 (0.36) 
25 0/3 - 3/3 31.87 (0.34) 3/3 34.27 (0.35) 3/3 32.71 (1.38) 
10 0/3 - 3/3 33.39 (0.16) 3/3 36.16 (0.49) 3/3 32.74 (0.53) 
5 0/3 - 3/3 34.33 (0.38) 3/3 36.89 (0.29) 3/3 34.22 (0.45) 
1 0/3 - 1/3 35.61 1/3 38.18 3/3 33.55 (0.69) 
0 0/3 - 0/3 - 0/3 - 3/3 33.59 (1.59) 
27 
 
D
N
A
 
t
e
m
p
l
a
t
e
 
v
o
l
u
m
e
:
 
1
0
µ
L
 
10 0/3 - 3/3 36.45 (0.56) 3/3 35.09 (0.44) 3/3 34.46 (0.27) 
5 0/3 - 3/3 33.47 (0.09) 3/3 36.11 (0.18) 3/3 33.96 (0.19) 
1 0/3 - 3/3 32.52 (0.35) 3/3 39.23 (0.69) 3/3 34.76 (0.84) 
0 0/3 - 0/3 - 0/3  2/3 34.06 (2.01) 
 427 
 428 
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Table 4. Patient demographics and diagnosis of IA according to the revised EORTC-MSG definitions 19 429 
Demographic Proven/Probable IA (n=10) Possible IA (=2) NEF (n=27) 
Male/Female 6/4 1/1 15/12 
Median age (range) 60.5 (25-74) -  (18-51) 56 (21-76) 
Underlying condition (N) AML (7)  
ALL (2) 
MDS (1) 
AML (1) 
ALL (1) 
AML (17) 
Lymphoma (6) 
AA (2) 
 ALL (1) 
MDS (1) 
Allogeneic Stem cell 
transplantation (N) 
6 2 19 
Fungal Prophylaxis (N) Fluconazole (9) Fluconazole (2) Fluconazole (15) 
Voriconazole (1) 
Fungal Disease 
Manifestation (N) 
Proven Aspergillus Sinusitis (1) 
Probable IPA (6) 
Probable IPA/Sinusitis (2) 
Probable Sinusitis (1) 
Possible IPA (2) N/A 
 430 
Key: AA:   Aplastic Anaemia 431 
AML:   Acute Myeloid Leukaemia 432 
ALL:   Acute lymphoblastic Leukaemia 433 
MDS:  Myelodysplastic syndrome 434 
Lymphoma:  Hodgkins, Non-Hodgkins and Burkitts Lymphoma 435 
IPA:   Invasive pulmonary aspergillosis 436 
N/A:   Not applicable 437 
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Table 5. Clinical Performance of AsperGenius® Species assay when testing serum from haematology 438 
with proven/probable IA (n=10), possible IA (n=2) and with no evidence of fungal disease (NEF, 439 
n=27). Performance represents a combination of results for the A. fumigatus specific and the broad 440 
range Aspergillus species assays, as in a clinical scenario a positive result in either assay would carry 441 
significance.   442 
Parameter  
 
Population 
Proven/Probable IA vs NEF Proven/Probable/Possible IA vs NEF  
Single Positive 
Threshold 
Multiple (≥2) 
positive threshold 
Single Positive 
Threshold 
Multiple (≥2) 
positive threshold 
Sensitivity 
(n/N, %, 95% CI) 
8/10,  
80.0% (49.0-94.3) 
5/10, 
50.0% (23.7-76.3) 
8/12,  
66.7% (39.1-86.2) 
5/12, 
41.7% (19.3-68.1) 
Specificity 
(n/N, %, 95% CI) 
21/27,  
77.8% (59.2-89.4) 
27/27 
100%, (87.5-100) 
21/27,  
77.8% (59.2-89.4) 
27/27 
100%, (87.5-100) 
LR +tive 3.6 >500* 3.0 >417* 
LR -tive  0.26 0.5 0.43 0.44 
DOR 14.0 >1000* 7.0 >947.7* 
*To overcome infinity the parameter determined using a specificity value of 99.9% 443 
Key: 444 
IA: Invasive Aspergillosis 445 
NEF:  No evidence of fungal disease 446 
LR: Likelihood ratio 447 
DOR: Diagnostic odds ratio 448 
 449 
450 
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Figure 1. Standard curves for the PathoNostics AsperGenius® A. fumigatus and Aspergillus species 451 
assays testing A. fumigatus genomic DNA extracted from plasma samples by a) Qiagen EZ1 and b) 452 
BioMerieux EasyMag automated extractors, and c) the A. terreus and Aspergillus species assays 453 
testing A. terreus genomic DNA extracted from plasma samples by BioMerieux EasyMag automated 454 
extractor. 455 
   456 
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Figure 2. PathoNostics AsperGenius® PCR positivity according to sampling for the cases of proven/probable invasive aspergillosis. Grey cells represent 460 
positive results with the number representing the corresponding Cq value.  461 
Patient  
(EORTC/MSG 
diagnosis)19 
Sample  
1 2 3 4 5 6 7 8 
Afumi Asp Afumi Asp Afumi Asp Afumi Asp Afumi Asp Afumi Asp Afumi Asp Afumi Asp 
1 (Probable IA) - - - - - - - - 38.0 37.1 37.0 36.1 37.6 36.5 NT NT 
2 (Probable IA) - - - 37.1 - - - - - 33.1 40.4 32.6 - 36.0 NT NT 
3 (Probable IA) - 33.2 - 34.7 - - - - - - - - - - - - 
4 (Probable IA) - - - - - 42.2 - - - - - - - - NT NT 
5 (Prob Asp Sin) 37.7 36.2 - - - - - - - - - - - - NT NT 
6 (Probable IA) - - - 37.0 - - - - - - - - 35.8 34.7 NT NT 
7 (Probable IA*) - - 44.8 38.7 - - - - - - - - - - - - 
8 (Probable IA) 34.3 31.8 44.7 36.8 37.4 34.7 46.3 37.6 - - - - NT NT NT NT 
9 (Probable IA) - - - - - - - - - - - - - - NT NT 
10 (Prov Asp Sin) - - - - - - - - - - - - - - NT NT 
 462 
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 463 
Key:  464 
Afumi: Pathonostics AsperGenius® A. fumigatus assay 465 
Asp:  PathoNostics AsperGenius® Species assay 466 
IA:  Invasive aspergillosis 467 
Probable IA*: Patient had a total of nine samples tested, the one additional sample tested was negative by both the A. fumigatus and species assays and 468 
was the last sample to be tested. It was excluded to avoid presentation difficulties. 469 
Prob Asp Sin: Probable Aspergillus sinusitis 470 
Prov Asp Sin: Proven Aspergillus sinusitis 471 
NT:  No sample tested 472 
-:  Assay was negative 473 
 474 
 475 
 476 
